Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Subscribe to Pharma in Focus

Sign Up Now

Pharma in Focus is considered essential daily reading in the Australian and NZ pharma industry.

In production for 14 years, it is emailed twice daily to more than 11,000 pharma industry professionals throughout Australia and NZ.

For just $454.50 a year (plus GST) Pharma in Focus puts you ahead of the game by delivering:

  • Key Aussie & NZ pharma news every working day
  • Daily in-depth features covering all aspects of pharma from drug approvals to employment issues
  • Full coverage and analysis of PBAC, PBS and TGA decisions
  • Ten survey-based white papers per year (total value $1500)

New to Pharma in Focus? Sign up below for your FREE two week trial.

Time to subscribe? Sign up below for your 12 month subscription.

Need multiple licenses? We have great corporate rates. Contact our friendly subscription managers on 02 9939 1881 or for our latest prices.

3 Simple Steps

1 Fill in your details below and submit

2 Make your subscription choice

3 Make your payment choice (Credit Card, Direct Deposit or Cheque)

Pipeline Monitor
Janssen's Humira-topping med approved
After a shortened review process, Janssen's new, first-up IL-23 blocker has been approved for severe plaque psoriasis in the US.
PBS clawback heads for day in court
The Commonwealth's attempt to claw back PBS cash from Sanofi that it says should never have been paid is due in court again next month but, big money aside, what's the point now?
Approvals Action
Roche's star MS drug approved
Roche has won approval for a new first-in-class multiple sclerosis drug just a week after the PBAC considered it for reimbursement.